EMMAC and University of Insubria to present abstract at IACM 10th Conference on Cannabinoid in Medicine

31 October 2019, London. EMMAC Life Sciences Group, Europe’s leading independent cannabis company, announces that the manuscript, “Immunomodulatory Effect of Cannabidiol: Relevance in Multiple Sclerosis” has been selected for presentation at the annual conference of the International Association for Cannabis as Medicine (IACM), the 10th Cannabinoid Conference 2019, in Berlin today.

The aim of the abstract and poster is to assess the immunomodulating potential of CBD which so far has had little attention. The study evaluates the effect of CBD on human peripheral blood mononuclear cells (PMBC) functional responses, including cell proliferation and cytokine production, and is part of a long-term research programme on the screening of Cannabinoids through an ex vivo/ in vitro human immune cells-based platform. The programme aims to investigate mechanisms of action and characterise cannabis-based medicinal products in disease models with a particular focus on spasticity, inflammation and chronic pain.

The abstract and poster has also been selected for publication in ‘Cannabis and Cannabinoid Research’, the only peer-reviewed journal dedicated to the scientific, medical and psychosocial exploration of clinical cannabis, cannabinoids and the endocannabinoid system, the official journal of the International Cannabinoid Research Society (ICRS) and the International Association for Cannabis as Medicine (IACM).

Barbara Pacchetti, Chief Scientific Officer of EMMAC, commented: “At EMMAC we believe the growth of medical cannabis must be underpinned by the most robust science, and we are pleased to be presenting this abstract at the IACM conference as we investigate the mechanisms of cannabis-based medicinal products with focus on spasticity, inflammation and chronic pain in multiple sclerosis and other diseases.

EMMAC is working with some of the world’s leading academic institutions such as the University of Insubria and Imperial College London to advance the industry’s understanding of the benefits of medical cannabis and we look forward to updating our stakeholders with
our progress.”


EMMAC Life Sciences Group is Europe’s leading independent cannabis company, bringing together pioneering science and research with cutting-edge cultivation, extraction and production. With a unique supply and distribution network throughout Europe, EMMAC’s
vision is to bring the life-enhancing potential of cannabis to the people who need it.


The Center for Research in Medical Pharmacology at the University of Insubria is an international leading center in the emerging field of neuroimmune pharmacology, a young but rapidly growing discipline encompassing interdisciplinary research in pharmacology, immunology and neuroscience, with the overarching goal to identify novel therapeutic approaches thanks to the investigations of the neuroimmune network. Basic and clinical research focus on the pathophysiology and therapeutics of major diseases such as multiple sclerosis, Parkinson’s disease, atherosclerosis and other immunoinflammatory-based disease. Clinical pharmacology, pharmacogenetics, pharmacoepidemiology and pharmacovigilance are included among the interests and approaches of the Center.


For scientific enquiries please contact research@emmac.com
For general enquiries please contact info@emmac.com or visit www.emmac.com

Media enquiries:

Henry Harrison-Topham / Jamie Hooper Tel: +44 (0) 20 7466 5000
emmac@buchanan.uk.com www.buchanan.uk.com


All statements, other than statements of historical fact, in this news release are forward looking statements that involve various risks and uncertainties, including, without limitation, statements regarding potential values, the future plans and objectives of EMMAC Life Sciences Ltd. There can be no assurance that such statements will prove to be accurate, achievable or recognisable in the near term.
Actual results and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management on the dates they are made and are expressly
qualified in their entirety by this notice. EMMAC Life Sciences Ltd assumes no obligation to update forward-looking statements should circumstances or management’s estimates or opinions change.